CancerCE.org is a dedicated portal of continuing education initiatives across tumor types. Peruse our previous offerings and stay tuned for additional CE activities for the oncology health care professional. CancerCE.org is produced by Terranova Medica, LLC.
Oncolytic therapy, introduced a decade ago, is gaining momentum as a promising treatment for melanoma. Advanced practice providers play a key role in implementing therapies like intralesional injections and require education, skill development, and credentialing support as they adopt oncolytic virotherapy. This APSHO-endorsed curriculum offers didactic content, instructional videos, and future hands-on training opportunities to support the expanded use of oncolytic therapies in clinical practice.
Oncolytic therapy was first introduced in the field of oncology a decade ago. Recently, advancements have been made in oncolytic therapy, with the promise of potentially transforming the melanoma treatment landscape. In these two 1.5-hour JADPRO Live classes on October 23, 2025, participants will have the opportunity to gain hands-on training experience in injecting different types of melanoma lesions. This training opportunity has been designed to complement the above activity, Oncolytic Therapy for Melanoma: An APP-focused Educational Curriculum.
Are you interested in participating in this exclusive training opportunity? If you are interested in the care of patients with melanoma and are planning to attend JADPRO Live 2025, please fill out this interest form. We will contact you individually about availability for these exclusive sessions.
**No Longer Available for Credit**
With an expanded array of therapeutic options for Stage IV melanoma, clinicians must grapple with increased complexity for decision making. This multimedia, interactive activity, Stage IV Melanoma: Strategies to Support Shared Decision Making uses cases to illustrate state-of-the art management of Stage IV melanoma. The activity also illustrates how to use the AIM at Melanoma Stage IV melanoma decision-making support tool Stage IV melanoma decision-making support tool and Patient Action Plans to support shared decision making. The esteemed faculty, Drs Anna Pavlick and Sunandana Chandra, also illustrate effective communication strategies and multidisciplinary approaches to provide streamlined care and consistent education and patient engagement across the oncology care team.
**No Longer Available for Credit**
Join our esteemed faculty—Krista M. Rubin, RN, MS, FNP-BC, and Ryan J. Sullivan, MD—as they explore optimal incorporation of targeted therapy in melanoma. This case addresses BRAF testing, appropriate use of BRAF/MEK inhibitor therapy, the profiles of the 3 targeted therapy options, side-effect management, and adherence/pharmacologic considerations.
Click here to learn more and view the accreditation info.
**No Longer Available for Credit**
This activity is designed to assist you in incorporating the Care Step Pathways and other tools of the Melanoma Nursing Initiative (TheMelanomaNurse.org) in clinical practice. Below are 5 cases representing patients at varied stages of melanoma and receiving the range of newer melanoma therapeutic options. As you go through each case, you will answer questions related to side-effect management and patient engagement over the treatment course. Each case is followed by a series of posttest questions to ascertain the extent of your learning. We hope you find this activity helpful to you as you work to improve outcomes for your patients with melanoma.